Consensus ARS Pharmaceuticals, Inc.

Stocks

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-24 EDT			5-day change	1st Jan Change
5.940 ^USD	-1.00%		-15.14%	-49.01%

07-17	Ars Pharmaceuticals, Inc. Announces Management Changes, Effective July 15, 2026	CI
07-07	ARS Pharmaceuticals, Inc. Announces Appointment of Donn Casale as Director, Effective July 7, 2026	CI

Evolution of the Average Target: ARS Pharmaceuticals, Inc.

Evolution of the Target Price: ARS Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ARS Pharmaceuticals, Inc.

1bd42a460969cb4cbb84a.1Hum0hlOks1mfgxCQx3qGid96ns6XsWkUC_jAVWvolE.kTHfuVgl24FVS18XK2eDQkMTplZXMq7VGRbRaB_1xTWaOcC3QBjiuC8wZw~38a80cb2b0dbc763f8cc12eb15001158

Analysts' recommendations: ARS Pharmaceuticals, Inc.

25-09-04	Roth Capital Initiates ARS Pharmaceuticals at Buy With $40 Price Target	MT
25-02-10	Oppenheimer Initiates ARS Pharmaceuticals at Outperform	MT
24-08-20	Cantor Fitzgerald Initiates ARS Pharmaceuticals at Overweight With $30 Price Target	MT
24-08-13	Raymond James Upgrades ARS Pharmaceuticals to Strong Buy From Outperform, Adjusts Price Target to $22 From $18	MT
24-07-25	Raymond James Starts ARS Pharmaceuticals With Outperform Rating	MT
24-03-05	Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6	MT
24-02-20	William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform	MT
24-02-06	Wedbush Raises ARS Pharmaceuticals' PT to $19 From $13 After Model Adjustments, Keeps Outperform Rating	MT
23-11-13	Wedbush Raises ARS Pharmaceuticals' PT to $13 From $5, Says Market Opportunity Intact; Maintains Outperform Rating	MT
23-09-20	William Blair Downgrades ARS Pharmaceuticals to Market Perform From Outperform	MT
23-06-21	Wedbush Trims ARS Pharmaceuticals' PT to $15 From $17, Adjusts US, EU Launch Estimates, Lowers Peak Penetration for neffy/Anaphylaxis in US; Keeps Outperform Rating	MT
23-01-31	Wedbush Initiates ARS Pharmaceuticals at Outperform With $10 PT, Says Neffy Intranasal Spray Set to Shake Up Epinephrine Market	MT
23-01-04	William Blair Initiates ARS Pharmaceuticals With Outperform	MT
22-12-13	SVB Securities Initiates ARS Pharmaceuticals With Outperform Rating, Price Target is $14	MT
22-05-16	Stifel Adjusts Price Target on Silverback Therapeutics to $5 From $6, Reiterates Hold Rating	MT
22-04-04	Goldman Sachs Downgrades Silverback Therapeutics to Neutral From Buy, Adjusts Price Target to $3.50 From $25	MT
22-04-01	JonesTrading Downgrades Silverback Therapeutics to Hold From Buy	MT
22-04-01	SVB Leerink Downgrades Silverback Therapeutics to Market Perform from Outperform, Adjusts Price Target to $1.80 from $25	MT
22-04-01	HC Wainwright Downgrades Silverback Therapeutics to Neutral from Buy	MT
22-04-01	Stifel Downgrades Silverback Therapeutics to Hold from Buy, Adjusts Price Target to $6 from $32	MT
21-11-12	SVB Leerink Adjusts Silverback Therapeutics' Price Target to $25 From $42, Keeps Outperform Rating	MT
21-08-16	SILVERBACK THERAPEUTICS : SVB Leerink Adjusts Silverback Therapeutics' Price Target to $49 from $46, Keeps Outperform Rating	MT
21-05-27	SILVERBACK THERAPEUTICS : JonesTrading Starts Silverback Therapeutics at Buy With $50 Price Target	MT
21-05-24	SILVERBACK THERAPEUTICS : SVB Leerink Adjusts Price Target on Silverback Therapeutics to $46 From $49, Maintains Outperform Rating	MT
21-04-06	SILVERBACK THERAPEUTICS : SVB Leerink Adjusts Price Target on Silverback Therapeutics to $49 From $40, Maintains Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARS PHARMACEUTICALS, INC.					+350.34%
	LONZA GROUP AG					+23.65%
	REVOLUTION MEDICINES, INC.					+9.39%
	BEONE MEDICINES AG					+27.54%
	IQVIA HOLDINGS INC.					+11.51%
	CELLTRION, INC.					+44.52%
	MEDPACE HOLDINGS, INC.					-5.11%
	ASCENDIS PHARMA A/S					+19.91%
	EUROFINS SCIENTIFIC SE					+8.58%
	ICON PUBLIC LIMITED COMPANY					+9.68%
	Average					+50.00%
	Weighted average by Cap.					+19.58%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.940USD

Average target price

26.75USD

Spread / Average Target

+350.34%

High Price Target

32.00USD

Spread / Highest target

+438.72%

Low Price Target

21.00USD

Spread / Lowest Target

+253.54%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Roth Capital Partners
Oppenheimer
Leerink Partners
William Blair & Co.
Wedbush
SVB Securities LLC
Stifel Nicolaus
Goldman Sachs
HC Wainwright
SVB Leerink
JonesTrading Institutional Services